Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q
20 mars 2024 07h00 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (Nasdaq:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO), announced today it received...
Attention Avid Bioservices Investors: Company Investigated by the Portnoy Law Firm
07 mars 2024 14h59 HE
|
Portnoy Law
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, March 07, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Avid Bioservices, Inc....
Avid Bioservices Announces Pricing of Private Placement of Convertible Notes
06 mars 2024 23h58 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO), announced today the pricing...
Avid Bioservices Announces Proposed Private Placement of Convertible Notes
06 mars 2024 16h32 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO), announced today that it...
Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024
06 mars 2024 16h31 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2023
07 déc. 2023 16h05 HE
|
Avid Bioservices, Inc
-- Recorded Second Quarter Revenue of $25.4 Million -- -- Signed $35 Million in Net New Business Orders Resulting in a Backlog of $199 Million -- -- Entered into Partnership with California...
Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2024 After Market Close on December 7, 2023
30 nov. 2023 16h05 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices Partners With California Institute for Regenerative Medicine (CIRM) to Provide CDMO Services for Cell and Gene Therapy (CGT) Programs
08 nov. 2023 08h05 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices Completes Construction of New, World-Class Cell and Gene Therapy Development and Manufacturing Facility
17 oct. 2023 08h05 HE
|
Avid Bioservices, Inc
Avid completes construction of cell and gene theapy facility bringing total revenue generating capacity to up to ~$400 Million annually
Avid Bioservices to Participate in RBC Capital Markets Virtual CDMO Conference
26 sept. 2023 16h05 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...